THE MATERHORN Fernando, H. J. S.; Pardyjak, E. R.; Di Sabatino, S. ...
Bulletin of the American Meteorological Society,
11/2015, Letnik:
96, Številka:
11
Journal Article
Recenzirano
Odprti dostop
Emerging application areas such as air pollution in megacities, wind energy, urban security, and operation of unmanned aerial vehicles have intensified scientific and societal interest in mountain ...meteorology. To address scientific needs and help improve the prediction of mountain weather, the U.S. Department of Defense has funded a research effort—the Mountain Terrain Atmospheric Modeling and Observations (MATERHORN) Program—that draws the expertise of a multidisciplinary, multiinstitutional, and multinational group of researchers. The program has four principal thrusts, encompassing modeling, experimental, technology, and parameterization components, directed at diagnosing model deficiencies and critical knowledge gaps, conducting experimental studies, and developing tools for model improvements. The access to the Granite Mountain Atmospheric Sciences Testbed of the U.S. Army Dugway Proving Ground, as well as to a suite of conventional and novel high-end airborne and surface measurement platforms, has provided an unprecedented opportunity to investigate phenomena of time scales from a few seconds to a few days, covering spatial extents of tens of kilometers down to millimeters. This article provides an overview of the MATERHORN and a glimpse at its initial findings. Orographic forcing creates a multitude of time-dependent submesoscale phenomena that contribute to the variability of mountain weather at mesoscale. The nexus of predictions by mesoscale model ensembles and observations are described, identifying opportunities for further improvements in mountain weather forecasting.
Celotno besedilo
Dostopno za:
BFBNIB, DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Automatically maintained self-injurious behavior (SIB) is one of the most challenging maladaptive behaviors to treat and often requires intensive behavioral treatments. Response blocking has been ...used as a treatment for SIB but is difficult to implement for long periods. In the current study, we demonstrated the utility of stimulus-control procedures to augment an intensive response blocking intervention for automatically maintained SIB in an adolescent male with multiple disabilities. Using a multiple schedule, we alternated between treatment paired with an arbitrary stimulus (the “consequence” component) and a “no-consequence” component, resulting in substantial reductions in SIB only in the consequence component. Measurement of the response latency from presentation of the stimulus to the first attempt or instance of SIB demonstrated stimulus control. This study adds to a small number of studies demonstrating inhibitory stimulus control over undesired behaviors and is the first known application to SIB. Implications for practice and future research are discussed. (PsycInfo Database Record (c) 2024 APA, all rights reserved) (Source: journal abstract)
Background: The dosage of carboplatin in cats has been reported anecdotally and experimentally in non‐tumor‐bearing cats, but the dosage for carboplatin treatment in tumor‐bearing cats has yet to be ...defined in a prospective clinical trial.
Purpose: To determine the maximally tolerated dose (MTD) and dose‐limiting toxicosis (DLT) of carboplatin in tumor‐bearing cats.
Cats: Fifty‐nine cats with measurable solid tumors.
Methods: The starting dose of carboplatin was 160 mg/m2 of body surface area IV. Doses were increased by 20 mg/m2 in cohorts of 3–14 cats until the MTD was reached.
Results: The 59 cats entered into this multi‐institutional phase I study received 1 or more doses of carboplatin at various dosages and were evaluated for toxicity, response to treatment, or both. The MTD was 240 mg/m2 and neutropenia was the DLT. For the 1st cycle of treatment in 44 cats evaluated for neutropenia, 6 episodes of grade 3 or greater neutropenia occurred on days 7 (n=1), 14 (n=4), and 21 (n=1). There was no evidence of drug‐induced nephrotoxicosis or pulmonary edema. Preliminary evidence of antitumor activity was observed in 7 of 59 (11.9%; 95% CI, 5.6–22.8%) cats evaluated for response to treatment. There was 1 complete response (cutaneous hemangiosarcoma) and 6 partial responses (4 injection site sarcomas, 1 oral squamous cell carcinoma, 1 lymphoma). Responses were of short duration (median, 42 days; range, 7–168 days).
Conclusions and Clinical Importance: The dose of carboplatin recommended to treat tumor‐bearing cats is 240 mg/m2 IV every 3–4 weeks.
SUPPLEMENT Fernando, H. J. S.; Pardyjak, E. R.; Di Sabatino, S. ...
Bulletin of the American Meteorological Society,
11/2015, Letnik:
96, Številka:
11
Journal Article
Recenzirano
Celotno besedilo
Dostopno za:
BFBNIB, DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
The purpose of this randomized, multicenter study was to evaluate the toxicity and efficacy of liposome‐encapsulated doxorubicin (LED) and doxorubicin (DOX) in the treatment of feline ...vaccine‐associated sarcoma (VAS). Cats were divided according to their disease status into a microscopic arm (no evidence of gross disease) and a macroscopic arm (evidence of gross disease). Each arm was randomized to receive either LED (1–1.5 mg/kg IV q3 weeks) or DOX (1 mg/kg IV q3 weeks). Thirty‐three cats were entered in the macroscopic arm of the study with an overall response rate of 39% (5 complete response and 8 partial response) and a median time to progression of 84 days. Response rates were not different between LED and DOX. Seventy‐five cats were entered into the microscopic arm. When compared to a similar historical control population treated with surgery alone, the cats receiving chemotherapy had a prolonged median disease‐free interval (388 days versus 93 days). No difference in efficacy was detected between LED and DOX. LED at 1.5 mg/kg induced delayed nephrotoxicosis in 23%, necessitating a decrease in the recommended dosage to 1 mg/kg, and cutaneous toxicosis in 21.7% of treated cats. This study showed that both DOX and LED are efficacious in the treatment of VAS and should be considered in the treatment of this tumor.
A multimethod, multisource assessment of impulsivity was conducted in a sample of more than 400 boys who were members of a longitudinal study of the development of antisocial behavior. Exploratory ...and confirmatory factor analysis of the 11 different impulsivity measures revealed two impulsivity factors: Cognitive and Behavioral. Cognitive and behavioral impulsivity had similar correlations with socioeconomic status. Cognitive impulsivity was more strongly related to IQ than was behavioral impulsivity. Behavioral impulsivity was more strongly related to delinquency at ages 10 and 12-13 than was cognitive impulsivity. Consistent with theoretical prediction, our results also indicate that behavioral impulsivity was especially related to serious delinquency that is stable over time.
Fourteen cats with advanced mammary adenocarcinoma were treated with doxorubicin HCl and cyclophosphamide. All cats had inoperable or recurrent disease, and 9 cats had metastasis to the thorax. ...Eleven of the cats were available for long-term evaluation; 3 had complete response to chemotherapy, with survival times of 180, 283, and 344 days; 2 had partial response, with survival times of 45 and 149 days; 2 had stabilization of disease, with survival times of 170 and 182 days; and 4 had no response, with survival times of 4, 47, 67, and 106 days.
Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to ...clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p < 0.02), and overall survival (p < 0.005) when compared with clinical stage III cats.
Malignant pilomatricoma in a dog Goldschmidt, M H; Thrall, D E; Jeglum, K A ...
Journal of cutaneous pathology,
October 1981, Letnik:
8, Številka:
5
Journal Article
Recenzirano
A malignant pilomatricoma is described in a dog. The primary tumor apparently developed in the metatarsal area where there were multiple intradermal skin nodules. Lymphatic invasion by tumor cells ...resulted in metastasis to the mammary glands, lymph nodes and lungs. The tumor is compared to the pilomatricoma in man where no metastasizing types have been identified.
PDF
